BlueSphere Bio

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 1/2
HA-1 (minor histocompatibility antigen)Cell therapy
Acute Myeloid Leukemia
Phase 1
Mutant NPM1 (NPM1c neoantigen), HLA-A*02:01-restrictedCell therapy
Acute Myeloid Leukemia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.